We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Marizomib Central Nervous System (CNS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05050305
Recruitment Status : Not yet recruiting
First Posted : September 20, 2021
Last Update Posted : July 15, 2022
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Clifton Mo, Dana-Farber Cancer Institute

Brief Summary:
This research is being done to test whether the investigational drug marizomib is safe and effective when used in combination with standard of care drugs for the treatment of multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma, Refractory Drug: Marizomib Drug: Pomalidomide Drug: Dexamethasone Phase 2

Detailed Description:

This is a Phase 2 single-arm study, incorporating two cohorts and using the combination of marizomib plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) patients and in RRMM patients with CNS involvement.

This research study involves a three drug chemotherapy regimen which includes taking the study drug marizomib, as well as pomalidomide and dexamethasone. The U.S. Food and Drug Administration (FDA) has not approved marizomib as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has approved pomalidomide and dexamethasone as a treatment option for multiple myeloma.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. As the study is looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose received will depend on the number of participants who have been previously enrolled in the study and how well participants have tolerated their doses. Participants will receive study treatment for as long as participants do not have serious side effects and their disease does not get worse.

It is expected that about 48 people will take part in this research study.

Bristol-Myers Squibb is supporting this research study by providing funding and study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS Myeloma
Estimated Study Start Date : March 2023
Estimated Primary Completion Date : December 2, 2023
Estimated Study Completion Date : December 2, 2025


Arm Intervention/treatment
Experimental: Marizomib plus pomalidomide and dexamethasone

A safety run-in using a modified 3+3 dose de-escalation design with relapsed/refractory multiple myeloma (RRMM) cohort, expanded to a total of 16 participants once recommended phase 2 does (RP2D) has been identified.

  • Marizomib (MRZ) at a pre-determined dose on Days 1, 8, 15, 22 of a 28 day study cycle
  • Pomalidomide (POM) at a daily predetermined dose on Days 1-21 of a 28 day study cycle
  • Dexamethasone (DEX) at a daily predetermined dose on Days 1, 2, 8, 9, 15, 16, 22, 23 of a 28 day study cycle

Simultaneously, relapsed/refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement cohort will receive an identical modified 3+3 dose de-escalation design and expanded to an efficacy-evaluable total of 30 patients once recommended phase 2 does (RP2D has been identified

Drug: Marizomib
Intravenous Infusion
Other Name: Salinosporamide A

Drug: Pomalidomide
Taken orally
Other Name: Pomalyst

Drug: Dexamethasone
Taken orally
Other Names:
  • Decadron
  • Dexasone
  • Hexadrol
  • Maxidex




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) Safety Run-In [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    MTD is defined as the highest dose level where no patients (of the 6 treated) develop a dose limiting toxicity (DLT)

  2. Dose Limiting Toxicity (DLT) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    Toxicity summaries will be stratified by dose level, grade, and treatment attribution

  3. The number and proportion of adverse events, graded as defined by CTCAE version 5.0. [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    CTCAE version 5.0.

  4. Overall response rate (ORR) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011).


Secondary Outcome Measures :
  1. Time to response (TTR) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011).

  2. Progression free survival (PFS) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first. up to 5 years ]
    Assessed using the updated International Myeloma Working Group Response Criteria

  3. Duration of response (DOR) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years ]
    Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011).

  4. Overall survival (OS) [ Time Frame: From date of enrollment until date of death from any cause, up to 5 years ]
    Assessed using the updated International Myeloma Working Group Response Criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment.
  • Patients in the CNS-involved cohort must have CNS involvement of MM as defined by meningeal myelomatosis and/or radiological evidence of leptomeningeal disease and/or intracranial plasmacytoma involving brain parenchyma.
  • Patients in the CNS-involved cohort must have received at least one or more previous lines of therapy including an IMiD and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • Patients in the RRMM cohort must have received at least two or more previous therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • Patients in the RRMM cohort must have measurable disease defined as at least one of the following:

    • Serum M protein ≥ 0.5 g/dL (≥5 g/L)
    • Urine M protein ≥200 mg/24 hours
    • Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)
  • Screening Laboratory evaluations within the following parameters

    • Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used within 14 days before first drug administration)
    • Platelet count ≥ 75,000 cells/dL (75 x 109/L) (without transfusions required during the 14 days prior to initiation of therapy)
    • Hemoglobin ≥ 8.0 g/dl (RBC transfusions are permitted)
    • Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
    • AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN
    • Calculated creatinine clearance ≥ 45 mL/min
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • All study participants must be registered into the mandatory POMALYST REMS® program, and be willing and able to comply with the requirements of the POMALYST REMS® program.
  • Females of reproductive potential must adhere to the scheduled testing as required in the POMALYST REMS® program.
  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
  • Patients have given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior exposure to marizomib. and primary refractoriness to pomalidomide or a pomalidomide combination. Prior pomalidomide exposure is permitted but patients must have shown tolerance (defined as no grade 3 or greater non-hematologic toxicity), as well as responsiveness to pomalidomide-based therapy (defined as MR or better).
  • Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy/watchful waiting.
  • Known GI disease or GI procedure that could interfere with the oral absorption of pomalidomide including difficulty swallowing.
  • Systemic treatment, within 14 days before the first dose of pomalidomide, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort.
  • Peripheral neuropathy ≥ Grade 3, or Grade 2 with pain on clinical examination during the screening period.
  • Any medical or psychiatric illness that in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study.
  • Current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, Grade 3 thromboembolic event or myocardial infarction within the past 6 months.
  • The following therapies within the stated time frames prior to initiation of therapy: previous cytotoxic therapies, including cytotoxic investigational agents, for MM within 3 weeks; IMiDs, PIs, corticosteroids, other approved therapeutics and monoclonal antibodies (Mabs) within 2 weeks; and investigational therapies within 4 weeks. Please note consideration of the interval for investigational agents from already approved classes of drug in MM (e.g. Cell-Mods, Mabs) can be considered on a case by case basis with the PI. Prior peripheral stem cell transplant within 12 weeks and the use of live vaccines within 30 days.
  • Prior allogeneic stem cell transplantation with active graft-versus-host-disease (grade 2 or greater).
  • Prior major surgical procedure or radiation therapy within 4 weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy).
  • Daily requirement for corticosteroids equivalent to > 10 mg/day prednisone, except for inhalation corticosteroids, for the RRMM cohort. For patients with CNS involvement who require a higher dose of corticosteroids for control of vasogenic edema (e.g. 16 mg/day dexamethasone), eligibility will be determined on a case-by-case basis after discussion with the PI.
  • Any > Grade 1 adverse reaction unresolved from previous treatments according to the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTC AE v.5.0). The presence of alopecia any grade or peripheral neuropathy ≤ Grade 2 without pain is allowed.
  • Concurrent symptomatic amyloidosis or plasma cell leukemia.
  • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
  • Known active infection requiring parenteral or oral anti-infective treatment within 7 days of start of therapy.
  • Known human immunodeficiency virus or active hepatitis C viral infection.
  • Active hepatitis B viral infection (defined as HBsAg+).

    • Patients with prior hepatitis B vaccine are permitted (defined as HBsAg-, Anti-HBs+, Anti-HBc-).
    • Non-active hepatitis B (HBsAg-, Anti-HBs+, Anti-HBc+) may be enrolled at the discretion of the investigator after consideration of risk of reactivation.
  • Pregnant or breast-feeding females.
  • Participants who are receiving any other investigational agents.
  • History of erythema multiforme or severe hypersensitivity to prior IMiD's®.
  • Inability to tolerate thromboprophylaxis.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known hypersensitivity to thalidomide or lenalidomide or other drugs included in this study.

The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar drugs.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05050305


Contacts
Layout table for location contacts
Contact: Clifton Mo, MD 617-632-4167 Clifton_Mo@DFCI.HARVARD.EDU

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Contact: Andrew Branagan, MD    617-724-4000    ABRANAGAN@PARTNERS.ORG   
Principal Investigator: Andrew Branagan, MD         
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Contact: Clifton Mo, MD    617-632-4167    Clifton_Mo@DFCI.HARVARD.EDU   
Principal Investigator: Clifton Mo, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Clifton Mo, MD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Clifton Mo, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT05050305    
Other Study ID Numbers: 20-551
First Posted: September 20, 2021    Key Record Dates
Last Update Posted: July 15, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Clifton Mo, Dana-Farber Cancer Institute:
Multiple Myeloma
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory
CNS Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Recurrence
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Dexamethasone
Pomalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents